Andrew Blauvelt

73PUBLICATIONS
154CO-AUTHORS
Clinical pharmacology and therapeuticsRadiation therapyPharmacogenomicsGene and molecular therapyDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (73)

|Aug 06, 2026
Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

|Jul 13, 2026
Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.

|Jun 01, 2026
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

|May 26, 2026
Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time.

|May 15, 2026
GRAPPA 2025 Collaborative Research Network Meeting: Difficult-to-Treat Psoriatic Arthritis and Future Strategies for Curing Psoriasis.

|Feb 05, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Andrew Blauvelt, H Chih-Ho Hong, Norito Katoh

Pageof 13

Frequent Collaborators

15 joint publications

Kim A Papp

14 joint publications

Kristian Reich

8 joint publications

April W Armstrong

7 joint publications

Melinda J Gooderham